Using antiviral treatment to prevent liver cancer in patients with hepatitis B and HIV
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
This study is looking to help people in Africa who have both hepatitis B and HIV by providing them with the right antiviral treatments to lower their chances of developing liver cancer, and it aims to improve healthcare and research in the region.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11175709 on NIH RePORTER |
What this research studies
This research focuses on reducing the incidence of hepatocellular carcinoma (HCC), a common and deadly cancer in Africa, particularly among individuals co-infected with hepatitis B virus (HBV) and HIV. The project involves forming a large cohort of patients from Uganda and Senegal, where participants will receive guideline-appropriate antiviral treatments aimed at interrupting the progression of HCC. The study aims to enhance the clinical and research infrastructure in sub-Saharan Africa, fostering collaboration between local and international researchers to address the burden of HCC. By investigating effective treatment strategies, the research seeks to improve patient outcomes and survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with chronic hepatitis B and HIV, particularly those residing in sub-Saharan Africa.
Not a fit: Patients without chronic hepatitis B or HIV, or those living outside the targeted regions of Uganda and Senegal, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of liver cancer in patients with HBV and HIV, leading to improved health outcomes.
How similar studies have performed: Previous research has shown promising results in using antiviral treatments to manage HBV and reduce associated cancer risks, indicating that this approach has potential for success.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Kirk, Gregory D — Johns Hopkins University
- Study coordinator: Kirk, Gregory D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.